Evidence map›Paper›PMID 34885044›Full record

ArticleCancers2021

Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety.

Judith Anna Delage, Silvano Gnesin, John O Prior, Jacques Barbet, Patricia Le Saëc, Séverine Marionneau-Lambot, Sébastien Gouard, Michel Chérel, Mickael Bourgeois, Niklaus Schaefer and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. From bench to bedside:EJNMMI research · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Judith Anna DelageRadiopharmacy Unit, Department of Pharmacy, Lausanne University Hospital and University of Lausanne, CH-1011 Lausanne, Switzerland.ORCID 0000-0003-3039-5173
Silvano GnesinInstitute of Radiation Physics, Lausanne University Hospital and University of Lausanne, CH-1011 Lausanne, Switzerland.ORCID 0000-0002-6547-3824
John O PriorDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, CH-1011 Lausanne, Switzerland.ORCID 0000-0003-1429-1374
Jacques BarbetGIP Arronax, F-44800 Saint-Herblain, France.
Patricia Le SaëcCRCINA, Inserm, CNRS, CHU Nantes, University of Nantes, F-44000 Nantes, France.
Séverine Marionneau-LambotCRCINA, Inserm, CNRS, CHU Nantes, University of Nantes, F-44000 Nantes, France.
Sébastien GouardCRCINA, Inserm, CNRS, CHU Nantes, University of Nantes, F-44000 Nantes, France.ORCID 0000-0002-0973-5420
Michel ChérelCRCINA, Inserm, CNRS, CHU Nantes, University of Nantes, F-44000 Nantes, France.ORCID 0000-0001-6347-6848
Mickael BourgeoisGIP Arronax, F-44800 Saint-Herblain, France.
Niklaus SchaeferDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, CH-1011 Lausanne, Switzerland.
David ViertlTranslational Radiopharmaceutical Sciences, Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, CH-1011 Lausanne, Switzerland.
Julie Katrin FierleLAbCore, Ludwig Institute for Cancer Research, Lausanne University Hospital and University of Lausanne, CH-1066 Epalinges, Switzerland.
Steven Mark DunnLAbCore, Ludwig Institute for Cancer Research, Lausanne University Hospital and University of Lausanne, CH-1066 Epalinges, Switzerland.
Alain Faivre-ChauvetCRCINA, Inserm, CNRS, CHU Nantes, University of Nantes, F-44000 Nantes, France.
Centre National de la Recherche Scientifique · FRUniversity of Lausanne · CHInstitut Génétique Nantes Atlantique · FRLudwig Cancer Research · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

1C1m-Fc, a promising anti-TEM-1 DOTA conjugate, was labeled with

Indexed as

copper-64dosimetryDOTA conjugationLutetium-177PET imagingtheranostictumor endothelial marker 1

Identifiers

PMID34885044
PMCPMC8657097
OpenAlexW3216503859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.